Evidence map›Paper›PMID 33580421›Full record

ReviewJournal of cancer research and clinical oncology2021

The tumor suppressor role of salvador family WW domain-containing protein 1 (SAV1): one of the key pieces of the tumor puzzle.

Ísis Salviano Soares de Amorim, Mariana Moreno de Sousa Rodrigues, Andre Luiz Mencalha

Open access · greenAbstract readReview
In one paragraph

Review in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Hongwu mixture exerts inhibition on triple-negative breast cancer by regulating SAV1/Hippo signaling through ZNF143.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ísis Salviano Soares de Amorim *Laboratório de Biologia Do Câncer, Instituto de Biologia Roberto Alcântara Gomes, Universidade Do Estado Do Rio de Janeiro, Av. 28 de Setembro, 87 fundos - 4º andar, Vila Isabel, Rio de Janeiro, RJ, CEP: 20551-030, Brazil.ORCID http://orcid.org/0000-0002-2762-1400
Mariana Moreno de Sousa RodriguesLaboratório de Biologia Do Câncer, Instituto de Biologia Roberto Alcântara Gomes, Universidade Do Estado Do Rio de Janeiro, Av. 28 de Setembro, 87 fundos - 4º andar, Vila Isabel, Rio de Janeiro, RJ, CEP: 20551-030, Brazil.
Andre Luiz MencalhaLaboratório de Biologia Do Câncer, Instituto de Biologia Roberto Alcântara Gomes, Universidade Do Estado Do Rio de Janeiro, Av. 28 de Setembro, 87 fundos - 4º andar, Vila Isabel, Rio de Janeiro, RJ, CEP: 20551-030, Brazil. andre.mencalha@uerj.br.ORCID http://orcid.org/0000-0003-3229-8094
Universidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn the complex tumor scenario, understanding the function of proteins with protumor or antitumor roles is essential to support advances in the cancer clinical area. Among them, the salvador family WW domain-containing protein 1 (SAV1) is highlighted. This protein plays a fundamental role in the tumor suppressor face of the Hippo pathway, which are responsible for controlling cell proliferation, organ size, development and tissue homeostasis. However, the functional dysregulation of this pathway may contribute to tumorigenesis and tumor progression. As SAV1 is a tumor suppressor scaffold protein, we explored the functions performed by SAV1 with its partners, the regulation of its expression, and its antitumor role in various types of cancer.

methodsWe selected and analyzed 80 original articles and reviews from Pubmed that focuses on the study of SAV1 in cancer.

resultsSAV1 interacts with several proteins, has different functions and acts as tumor suppressor by other mechanisms besides Hippo pathway. SAV1 expression regulation seems to occur by microRNAs and rarely by mutation or promoter methylation. It is downregulated in different types of cancer, which leads to cancer promotion and progression and is associated with poor prognosis. In vivo models have shown that the loss of SAV1 contributes to tumorigenesis.

conclusionSAV1 plays a relevant role as tumor suppressor in several types of cancer, highlighting SAV1 and the Hippo pathway's importance to cancer. Thus, encouraging further studies to include the SAV1 as a molecular key piece in cancer biology and in clinical approaches to cancer.

Indexed as

AnimalsCarcinogenesisCell Cycle ProteinsCell ProliferationHumansMicroRNAsNeoplasmsSignal TransductionTumor Suppressor ProteinsWW DomainsCell Cycle ProteinsMicroRNAsTumor Suppressor ProteinsCancerHippo pathwaySAV1Tumor suppressor

Identifiers

PMID33580421
PMCPMC11801967
OpenAlexW3126953129

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.